1953 Plans To Advance Into Pivotal Study For FDA Approval
08/12/2025 13:16
Dec 8 (Reuters) - Vyome Holdings Inc HIND.O: VYOME REPORTS POSITIVE FINAL PHASE 2 RESULTS FOR VT-1953; PLANS TO ADVANCE INTO PIVOTAL STUDY FOR FDA APPROVAL VYOME HOLDINGS INC - VT-1953 WAS WELL-TOLERATED, WITH NO NEW SAFETY CONCERNS OBSERVED VYOME HOLDINGS INC - TO ENGAGE WITH FDA TO DESIGN AND INITIATE A PIVOTAL PHASE III CLINICAL STUDY IN 2026 Source text: ID:nBw81dnSLa Further company coverage: HIND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vyome Holdings
See all newsBrief: Vyome - Appoints Jerry Leonard As CFO On August 27, 2026 - SEC Filing
Biopharma firm Vyome Holdings posts Q2 net loss
Vyome Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Vyome Holdings Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity